1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMiddle AgedNeoplasms, Radiation-InducedNeoplasms, Second PrimaryRadiotherapyRadiotherapy DosageRadiotherapy, AdjuvantRisk FactorsConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissions
1995
Second solid malignancies after combined modality therapy for Hodgkin's disease.
Doria R, Holford T, Farber L, Prosnitz L, Cooper D. Second solid malignancies after combined modality therapy for Hodgkin's disease. Journal Of Clinical Oncology 1995, 13: 2016-22. PMID: 7636543, DOI: 10.1200/jco.1995.13.8.2016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansIncidenceLymphoma, Non-HodgkinMaleMiddle AgedNeoplasms, Second PrimaryPoisson DistributionRadiation InjuriesRadiotherapyRadiotherapy DosageRecurrenceRemission InductionRisk FactorsConceptsSecond solid malignanciesActuarial incidenceRelative riskHodgkin's diseaseSolid tumorsGroup BRecurrent diseaseSolid malignanciesGroup AUntreated advanced Hodgkin's diseaseAdvanced Hodgkin's diseaseOverall relative riskLow-dose radiationSignificant increaseAdvanced diseaseUntreated patientsModality therapyHodgkin's lymphomaPatientsDiseaseCarcinogenic effectsChemotherapyLymphomaMalignancyCMT
1986
Prognostic indicators in diffuse large-cell (histiocytic) lymphoma
Todd M, Portlock C, Farber L, Holford T, Bertino J. Prognostic indicators in diffuse large-cell (histiocytic) lymphoma. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 593-601. PMID: 2422144, DOI: 10.1016/0360-3016(86)90068-4.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBleomycinBone MarrowCyclophosphamideCytarabineDoxorubicinFemaleHumansLeucovorinLymphoma, Large B-Cell, DiffuseMaleMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisVincristineConceptsDiffuse large cell lymphomaLarge cell lymphomaPrognostic groupsSystemic symptomsPrognostic indicatorAnn Arbor staging systemBone marrow involvementBulk of diseaseLactic dehydrogenaseDiffuse histiocytic lymphomaAnn Arbor classificationStage of diseaseReliable prognostic indicatorChemotherapy clinical trialsLukes-Collins classificationSerum lactic dehydrogenaseMarrow involvementOverall survivalCombination chemotherapyPrognostic factorsDisease involvementPathological criteriaStaging systemSpecific therapyHistiocytic lymphoma